Acquired idiopathic inflammatory myopathy
Therapeutic area
Neuromuscular Disease
Rare disease
Yes
- Definition
- An umbrella term for diseases which have chronic muscle inflammation and weakness of unknown etiology. The types of idiopathic inflammatory myopathy are further defined by either clinicopathologic criteria or by the presence of certain autoantibodies.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Acquired idiopathic inflammatory myopathy
- Therapeutic area
- Neuromuscular Disease
- acquired idiopathic inflammatory myopathy
- IIm
- IMM
- idiopathic inflammatory myopathies
- idiopathic inflammatory myositis
- idiopathic inflammatory myopathy, familial
- Disease mechanisms
- Inflammatory
- Severity
- Severe
- Neuromuscular Disease
- Rheumatology
- MONDO ID
- MONDO:0020122
- Parent condition
- MONDO:0016105
Related records
Broader conditions (14)
- Acquired skeletal muscle disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Human disease
- Idiopathic disease
- Idiopathic inflammatory myopathy
- Inflammatory disease
- Muscle tissue disorder
- Musculoskeletal system disorder
- Myopathy
- Myositis disease
- Skeletal muscle disorder
Narrower conditions (25)
- Adermatopathic dermatomyositis
- Adult dermatomyositis
- Amyopathic dermatomyositis
- Anti-MDA5 dermatomyositis
- Anti-Mi2 dermatomyositis
- Anti-NXP2 dermatomyositis
- Anti-SAE dermatomyositis
- Anti-TIF1 dermatomyositis
- Antisynthetase syndrome
- Classical dermatomyositis
- Clinically amyopathic dermatomyositis
- Dermatomyositis
- Eosinophilic fasciitis
- Focal myositis
- Hypomyopathic dermatomyositis
- Idiopathic eosinophilic myositis
- Immune-mediated necrotizing myopathy
- Inflammatory myopathy with abundant macrophages
- Juvenile dermatomyositis
- Juvenile idiopathic inflammatory myopathy
Trials (68)
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Study of AZD0120 in Autoimmune Diseases
- A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
- A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
- A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
- A Study of RD06-04 in Patients With Active Autoimmune Diseases
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
- A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Adult Autoimmune Myopathies (MAIA)
- AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
- Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
- Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
Drugs in development (3)
- Daxdilimab Phase 2
- Plamotamab Phase 1
- Rapcabtagene autoleucel Phase 2